Related Experiment Video
Updated: Mar 25, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Topical difluprednate monotherapy for uveitic macular edema
Richard J Symes1, Farzin Forooghian1
1Department of Ophthalmology, University of British Columbia, Vancouver, BC.
Objective:
To describe the use of topical difluprednate for the treatment of uveitic macular edema.
Design:
Retrospective review of 3 consecutive cases of uveitic macular edema.
Methods:
Patients were treated with topical difluprednate monotherapy.
Results:
All patients experienced complete resolution of uveitic macular edema within 2-4 weeks. We observed a statistically significant improvement in central subfield macular thickness (p = 0.04). There was an overall improvement in visual acuity, but this result was not statistically significant (p = 0.33).
Conclusions:
Topical difluprednate can be effective for uveitic macular edema. Further investigation of this therapy in prospective randomized controlled trials is warranted.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems
Nephrotic Syndrome II : Assessment and Medical Management

